PEPG Stock Overview
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PepGen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.93 |
| 52 Week High | US$17.51 |
| 52 Week Low | US$3.72 |
| Beta | 0 |
| 1 Month Change | -15.33% |
| 3 Month Change | 73.91% |
| 1 Year Change | -20.94% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -7.45% |
Recent News & Updates
Recent updates
PepGen: Long Road Ahead
Jan 20Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?
Nov 13
Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?
Jul 31We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth
Dec 31Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation
Sep 07PepGen GAAP EPS of -$1.23 misses by $0.47
Aug 12Shareholder Returns
| PEPG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.2% | 0.4% | 1.0% |
| 1Y | -20.9% | 0.9% | 21.9% |
Return vs Industry: PEPG underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: PEPG underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| PEPG volatility | |
|---|---|
| PEPG Average Weekly Movement | 21.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PEPG's share price has been volatile over the past 3 months.
Volatility Over Time: PEPG's weekly volatility has increased from 16% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 64 | James McArthur | pepgen.com |
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD.
PepGen Inc. Fundamentals Summary
| PEPG fundamental statistics | |
|---|---|
| Market cap | US$386.41m |
| Earnings (TTM) | -US$78.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.9x
P/E RatioIs PEPG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEPG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$78.63m |
| Earnings | -US$78.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PEPG perform over the long term?
See historical performance and comparison